In Brief: NAD trims BPI claims, formula price-fixing in China, FDA warns Formulife and identifies spiked supplements, NBTY’s consumer redress
This article was originally published in The Tan Sheet
Executive Summary
BPI discontinues claims at NAD’s behest; China levies fines for infant formula price-fixing; Public Citizen pans OTC Oxytrol; FDA advises ProNatural supplements cannot be topical; FDA warns Formulife on DMAA; FDA uncovers more spiked supplements; NBTY pays back consumers over omega-3 claims; Algean reminded about re-inspection fee.
You may also be interested in...
In Brief: Hormel Buys CytoSport, FDA Warns On Drug Claims, Mira Health Consent Decree
Hormel flexes Muscle Milk for protein; Hangover prevention claims are disease claims; Mira Health cannot resume supplement production without FDA permission; Batch production records require details; Laclede needs drug approval for vaginal products and U.S. & Korea ink organic equivalency agreement.
In Brief: Hormel Buys CytoSport, FDA Warns On Drug Claims, Mira Health Consent Decree
Hormel flexes Muscle Milk for protein; Hangover prevention claims are disease claims; Mira Health cannot resume supplement production without FDA permission; Batch production records require details; Laclede needs drug approval for vaginal products and U.S. & Korea ink organic equivalency agreement.
China Tightens Infant Formula Industry Oversight, Levels Playing Field
China steps up oversight of pricing and compliance in the infant formula industry, imposing requirements similar to those for drug manufacturers. To tighten supervision, CFDA publishes new rules on manufacturing and marketing that raise standards and prohibit promotion of formula to medical institutions.